Get the Stockscreener App
66.44
0.53%
0.35
Pre-market:
67.10
0.66
+0.99%
Disc Medicine Inc stock is traded at $66.44, with a volume of 455.57K.
It is up +0.53% in the last 24 hours and down -17.91% over the past month.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
See More
Previous Close:
$66.09
Open:
$66.09
24h Volume:
455.57K
Relative Volume:
0.85
Market Cap:
$2.55B
Revenue:
-
Net Income/Loss:
$-241.60M
P/E Ratio:
-10.04
EPS:
-6.6167
Net Cash Flow:
$-201.34M
1W Performance:
-3.96%
1M Performance:
-17.91%
6M Performance:
+11.46%
1Y Performance:
+6.49%
1-Day Range:
$64.31
$66.58
1-Week Range:
$64.31
$69.84
52-Week Range:
$40.00
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
Name
Disc Medicine Inc
Sector
Industry
Phone
(617) 674-9274
Address
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
66.44 | 2.55B | 0 | -241.60M | -201.34M | -6.6167 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Resumed | Stifel | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-11-25 | Resumed | Raymond James | Strong Buy |
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-04-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-23-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-01-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-09-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-07-23 | Initiated | H.C. Wainwright | Buy |
| May-17-23 | Initiated | Raymond James | Outperform |
| Apr-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-21-23 | Initiated | Stifel | Buy |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Mar-23-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Disc Medicine Inc Stock (IRON) Latest News
Disc Medicine Investor News: If You Have Suffered Losses in - GlobeNewswire
Behavioral Patterns of IRON and Institutional Flows - news.stocktradersdaily.com
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - PR Newswire
Disc Medicine, Inc. (NASDAQ:IRON) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Wells Fargo Maintains Disc Medicine(IRON.US) With Buy Rating, Raises Target Price to $86 - moomoo.com
Disc Medicine CEO Quisel John D Exercises Options, Holding 262,064 Shares Post-Transaction - Kalkine Media
Disc Medicine (IRON) Reports Encouraging RESTORE PV Data, Is The Stock Undervalued? - simplywall.st
Disc Medicine (NASDAQ: IRON) CEO turns 36,000 options into stock - Stock Titan
IRON Form 4 FilingsDisc Medicine, Inc. SEC Form 4 - Stock Titan
IRON Maintained by Wells Fargo -- Price Target Raised to $86.00 - GuruFocus
[Form 4] Disc Medicine, Inc. Insider Trading Activity - Stock Titan
Kevin Bitterman Sells 27,136 Shares of Disc Medicine (NASDAQ:IRON) Stock - MarketBeat
Squarepoint Ops LLC Increases Stock Position in Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine (NASDAQ:IRON) Raised to "Hold" at Wall Street Zen - MarketBeat
Officer at Disc Medicine (NASDAQ: IRON) plans to sell 27,136 shares - Stock Titan
Disc Medicine (NASDAQ:IRON) Shares Down 5%Should You Sell? - MarketBeat
The Technical Signals Behind (IRON) That Institutions Follow - Stock Traders Daily
Opaleye Management Inc. Raises Stock Position in Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine Shares Polycythemia Vera Data, Outlines Late 2026 Trial Milestones - Benzinga
IRON Reiterated by Wedbush -- Price Target Maintained at $100 - GuruFocus
Disc Medicine's Phase 2 rare blood cancer data; Frazier adds to public fund - Endpoints News
Form 8K Disc Medicine Inc For: 10 September By Investing.com - Investing.com South Africa
Disc Medicine reports promising DISC-3405 Phase 2 data - TipRanks
Disc Medicine's (IRON) "Outperform" Rating Reiterated at Wedbush - MarketBeat
Disc Medicine at Wells Fargo conference: two drug bets near key tests - Investing.com Canada
H.C. Wainwright reiterates Disc Medicine stock rating on trial data By Investing.com - Investing.com India
Disc Medicine reports Phase 2 DISC-3405 trial results - grafa.com
Jefferies reiterates Disc Medicine stock rating on polycythemia data By Investing.com - Investing.com Nigeria
Disc Medicine stock rating held at Outperform by BMO on trial data - Investing.com Canada
Disc Medicine reports positive phase 2 trial results for DISC-3405 By Investing.com - Investing.com South Africa
Disc Medicine (IRON) Reports Promising Phase 2 Data; Market Pric - GuruFocus
Disc Medicine reports positive phase 2 trial results for DISC-3405 - investing.com
Blood-removal procedures fell from 4.0 at baseline to 0.6 after treatment - Stock Titan
Insider Selling: Disc Medicine (NASDAQ:IRON) Director Sells $135,052.44 in Stock - MarketBeat
Disc Medicine (NASDAQ: IRON) director sells shares under preset plan - Stock Titan
Disc Medicine at cantorfitzgerald healthcare conference: pipeline nears key tests - Investing.com Canada
Disc Medicine faces class action over alleged m... - Pluang
Legal & General Group Plc Invests $1.35 Million in Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Small Disc Medicine (NASDAQ: IRON) shareholder sale planned - Stock Titan
Disc Medicine (NASDAQ: IRON) files notice to sell about $60K in stock - Stock Titan
Disc Medicine (NASDAQ: IRON) holder plans $72K stock sale - Stock Titan
Proposed $176K Disc Medicine (NASDAQ: IRON) share sale by Atlas Venture Fund X - Stock Titan
Kevin Bitterman Sells 129 Shares of Disc Medicine (NASDAQ:IRON) Stock - MarketBeat
Insider Selling: Disc Medicine (NASDAQ:IRON) Director Sells $3,941,477.88 in Stock - MarketBeat
Kevin Bitterman Sells 5,203 Shares of Disc Medicine (NASDAQ:IRON) Stock - MarketBeat
Disc Medicine (IRON) director's funds sell 54K shares in 10b5-1 trades - Stock Titan
Disc Medicine(IRON.US) Director Sells US$4.37 Million in Common Stock - Moomoo
Atlas fund plans small Disc Medicine (NASDAQ: IRON) share sale - Stock Titan
Venture fund plans Disc Medicine (IRON) share sale - Stock Titan
Disc Medicine (NASDAQ: IRON) investor plans $225K stock sale - Stock Titan
Disc Medicine Inc Stock (IRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
Disc Medicine Inc Stock (IRON) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bitterman Kevin | Director |
Sep 11 '26 |
Option Exercise |
45.07 |
27,136 |
1,223,144 |
27,136 |
| Bitterman Kevin | Director |
Sep 11 '26 |
Sale |
70.11 |
27,136 |
1,902,505 |
0 |
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):